Under the agreement, Biocytogen will provide Merck antibodies directed against at least three targets specified by them from Biocytogen's Project Integrum (also called HiTS Platform), which are generated by leveraging Biocytogen's proprietary RenMice^TM Platform. Merck will carry out feasibility tests and be responsible for further development and commercialization of the products if exercising an option. Additional targets subject to mutual discretion may be included under this agreement.

Dr. Yuelei Shen, President and CEO of Biocytogen, said: "Thanks to Merck's recognition of our proprietary platform and antibody discovery capabilities, we believe that differentiated candidates generated from our innovative models and discovery platform can quickly advance novel antibody-based therapeutics. Our RenMice^TM-based Project Integrum aims to discover antibodies against more than 1,000 targets. We welcome collaboration with partners worldwide to realize the full potential of this platform."